{"id":"W4401114827","doi":"10.1007/s13555-024-01224-x","title":"Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials","year":2024,"lang":"en","type":"article","venue":"Dermatology and Therapy","topic":"Psoriasis: Treatment and Pathogenesis","field":"Immunology and Microbiology","cited_by":7,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research; University of Toronto","funders":"Janssen Biotech; LEO Pharma; Regeneron Pharmaceuticals; Sun Pharma; Bristol-Myers Squibb; Eli Lilly and Company; Ortho Dermatologics; Incyte; Dermira; Celgene; Sanofi; Amgen; Pfizer","keywords":"Randomized controlled trial; Psoriasis; Medicine; Phase (matter); Physical therapy; Internal medicine; Dermatology; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006196848,0.0003824949,0.001292626,0.000151077,0.0002195781,0.00006781032,0.0001200718,0.0003213153,0.00004175435],"category_scores_gemma":[0.0002944996,0.0002004026,0.0001380472,0.0001571443,0.0002408645,0.0001342348,0.00004335534,0.0002147991,0.00002375457],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001178517,"about_ca_system_score_gemma":0.00005503232,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002197415,"about_ca_topic_score_gemma":0.00007190921,"domain_scores_codex":[0.9966857,0.001442563,0.0008724997,0.0005899696,0.00005062338,0.0003586487],"domain_scores_gemma":[0.9965332,0.002821037,0.000221309,0.0003194557,0.00005815948,0.00004685682],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6826383,0.0008098944,0.03074704,0.00001852392,0.007287393,0.0001659803,0.01057701,0.000002155218,0.001848865,0.0006611224,0.001174471,0.2640692],"study_design_scores_gemma":[0.9227992,0.001368701,0.04220851,0.0001963296,0.00104998,0.000230814,0.0006859101,0.00005043291,0.01585123,0.004076422,0.0105495,0.0009329241],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9813831,0.01343988,0.0000339671,0.002092228,0.0007281677,0.001610263,0.0005553217,0.00008689366,0.00007011697],"genre_scores_gemma":[0.9966798,0.001403969,0.00009048688,0.0008781576,0.00002337648,0.0002518491,0.0005226233,0.00002628733,0.0001234335],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2631363,"threshold_uncertainty_score":0.8172179,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02085379842455284,"score_gpt":0.2720310845102961,"score_spread":0.2511772860857432,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}